Get the Stockscreener App
62.65
0.90%
-0.57
After Hours:
62.39
-0.26
-0.42%
10 X Genomics Inc stock is traded at $62.65, with a volume of 1.47M.
It is down -0.90% in the last 24 hours and up +30.90% over the past month.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
See More
Previous Close:
$63.22
Open:
$62.54
24h Volume:
1.47M
Relative Volume:
0.47
Market Cap:
$8.16B
Revenue:
$638.78M
Net Income/Loss:
$-22.66M
P/E Ratio:
-359.23
EPS:
-0.1744
Net Cash Flow:
$122.18M
1W Performance:
+1.80%
1M Performance:
+30.90%
6M Performance:
+180.06%
1Y Performance:
+361.68%
1-Day Range:
$60.99
$63.48
1-Week Range:
$58.70
$63.89
52-Week Range:
$11.16
$66.94
10 X Genomics Inc Stock (TXG) Company Profile
Name
10 X Genomics Inc
Sector
Industry
Phone
(925) 401-7300
Address
6230 STONERIDGE MALL ROAD, PLEASANTON, CA
Compare TXG vs VEEV, BTSG, TEM, HQY
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
TXG
10 X Genomics Inc
|
62.65 | 8.32B | 638.78M | -22.66M | 122.18M | -0.1744 |
VEEV
Veeva Systems Inc
|
275.09 | 40.70B | 3.32B | 941.65M | 1.64B | 5.6161 |
BTSG
Brightspring Health Services Inc
|
60.73 | 11.78B | 13.65B | 169.86M | 412.12M | 1.0758 |
TEM
Tempus Ai Inc
|
64.62 | 12.03B | 1.36B | -302.91M | -219.93M | -1.7182 |
HQY
Healthequity Inc
|
96.07 | 8.72B | 1.34B | 230.70M | 440.96M | 2.6695 |
10 X Genomics Inc Stock (TXG) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-31-26 | Upgrade | William Blair | Mkt Perform → Outperform |
| Dec-11-25 | Downgrade | Citigroup | Buy → Neutral |
| Dec-02-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Sep-11-25 | Initiated | Piper Sandler | Neutral |
| Feb-13-25 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Sep-03-24 | Initiated | Leerink Partners | Outperform |
| Jul-22-24 | Upgrade | Jefferies | Hold → Buy |
| Jul-18-24 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-10-24 | Downgrade | Deutsche Bank | Buy → Hold |
| Jun-27-24 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| Jun-25-24 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-03-24 | Resumed | Jefferies | Hold |
| May-01-24 | Downgrade | TD Cowen | Buy → Hold |
| Dec-14-23 | Initiated | Guggenheim | Buy |
| Dec-13-23 | Initiated | Wolfe Research | Outperform |
| Dec-12-23 | Upgrade | BofA Securities | Underperform → Neutral |
| Jul-05-23 | Resumed | JP Morgan | Overweight |
| May-10-23 | Initiated | Barclays | Overweight |
| Mar-31-23 | Initiated | Stephens | Overweight |
| Feb-02-23 | Initiated | UBS | Neutral |
| Dec-14-22 | Initiated | Deutsche Bank | Buy |
| Aug-18-22 | Downgrade | Goldman | Neutral → Sell |
| Jul-25-22 | Initiated | Canaccord Genuity | Buy |
| Jul-15-22 | Downgrade | BofA Securities | Neutral → Underperform |
| Jul-15-22 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-15-21 | Resumed | Cowen | Outperform |
| Sep-14-21 | Downgrade | BofA Securities | Buy → Neutral |
| Mar-15-21 | Initiated | William Blair | Outperform |
| Dec-02-20 | Initiated | Goldman | Neutral |
| Sep-09-20 | Initiated | Morgan Stanley | Overweight |
| Jul-10-20 | Initiated | Stifel | Buy |
| Mar-05-20 | Initiated | Guggenheim | Buy |
| Jan-07-20 | Initiated | Citigroup | Buy |
| Oct-07-19 | Initiated | BofA/Merrill | Buy |
| Oct-07-19 | Initiated | Cowen | Outperform |
| Oct-07-19 | Initiated | JP Morgan | Overweight |
| Sep-24-19 | Initiated | Evercore ISI | Outperform |
View All
10 X Genomics Inc Stock (TXG) Latest News
10x Genomics (TXG) CEO holds 1,075,249 shares after 100-share gift - Stock Titan
Founder trust at 10x Genomics (NASDAQ: TXG) moves to sell 20,000 shares - Stock Titan
10x Genomics Rallies 84% in 3 Months: Is There More Upside Ahead? - Yahoo Finance
TXG Stock Price and Chart — NASDAQ:TXG - TradingView
A Look at 10x Genomics Inc (TXG) After 4.0% Decline -- GF Value $18.36 vs Price $60.00 - GuruFocus
RBC Capital initiates 10X Genomics stock with Sector Perform rating - Investing.com
10X GENOMICS, INC. : RBC INITIATES COVERAGE WITH SECTOR PERFORM RATING; TARGET PRICE $70 - Bitget
Jury Awards 10x Genomics Millions in Patent Lawsuit Against Qiagen Unit - Benzinga
TXG Stock Down Despite Patent Verdict Win Against Parse Biosciences - TradingView
Delaware jury finds Parse infringed three genetic-sequencing patents - Reuters
10x Genomics Inc (TXG) Shares Fall 5.1% -- GF Value Says Still O - GuruFocus
10x Genomics (TXG) CEO sells 10,486 shares under 10b5-1 plan - Stock Titan
10x Genomics wins jury award in Qiagen patent row (TXG:NASDAQ) - Seeking Alpha
10x Genomics CEO Serge Saxonov sells $667,900 in stock - Investing.com
10x Genomics Inc (TXG) Director Shehnaaz Suliman Sells 2,207 Sha - GuruFocus
10x Genomics (NASDAQ: TXG) CEO sells for taxes, still holds 1,085,835 shares - Stock Titan
10x Genomics (NASDAQ: TXG) CEO lines up another share sale - Stock Titan
10x Genomics (NASDAQ: TXG) exec to sell 16,614 shares - Stock Titan
10x Genomics (NASDAQ: TXG) insider plans sale of 17,948 shares - Stock Titan
10x Genomics (NASDAQ: TXG) holder to sell about $871K in stock - Stock Titan
10x Genomics (TXG) CEO gifts 4,000 shares in stock donation - Stock Titan
10x Genomics (NASDAQ: TXG) holder to sell 2,207 RSU shares - Stock Titan
10x Genomics: The Turnaround Is Real, But Atera Now Has To Deliver (Rating Upgrade) (TXG) - Seeking Alpha
Fed. Circ. Backs PTAB's Ax Of 10x Genomics Patent Claims - law360.com
Federal Circuit Upholds PTAB Obviousness Rulings Against Single Cell Sequencing Patents - IPWatchdog.com
10x Genomics Gains as Investors Extend Post-Earnings Rally on Atera Demand - Quiver Quantitative
10x Genomics’ Bid to Revive Patents Rejected by Federal Circuit - Bloomberg Law News
10x Genomics (NASDAQ:TXG) Reaches New 52-Week HighWhat's Next? - MarketBeat
10x Genomics stock hits 52-week high at $60.73 By Investing.com - Investing.com Australia
10x Genomics stock hits 52-week high at $60.73 - Investing.com
Bank of America Corp DE Has $20.48 Million Position in 10x Genomics $TXG - MarketBeat
Director Sarah Teichmann Sells 7,551 Shares of 10x Genomics Inc (TXG) - GuruFocus
10x Genomics (TXG) Sees Strong Early Orders for New Atera Platform - Yahoo Finance
A Look at 10x Genomics Inc (TXG) After 3.4% Gain -- GF Value $18 - GuruFocus
10x Genomics Inc (TXG) (Q2 2026) Earnings Call Highlights: Atera Launch Drives Record Demand Amidst Transition - GuruFocus
10x Genomics (NASDAQ: TXG) director sells under 10b5-1 plan - Stock Titan
7 Best Genomics Stocks for 2026 and How to Invest - The Motley Fool
symbol__ Stock Quote Price and Forecast - CNN
10x Genomics (TXG) Could Be 35% Above Fair Value Following 2026 Outlook Lift - Yahoo Finance
10x Genomics (TXG) Dips 3.5% to $56.09 as Support at $53.29 Comes Into ViewTrend Reversal Picks - Vinanet
5 Revealing Analyst Questions From 10x Genomics’s Q2 Earnings Call - Yahoo Finance
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital By Investing.com - Investing.com Canada
Cathie Wood’s ARK sells 10X Genomics stock, buys Perceptive Capital - Investing.com
A Look at 10x Genomics Inc (TXG) After 3.6% Decline -- GF Value $18.38 vs Price $56.09 - GuruFocus
TXG (TXG) insider schedules sale of common stock and notes prior sale - Stock Titan
ARK Investment Management (TXG) reports 10.0M-share position in 10x Genomics - Stock Titan
10x Genomics, Inc.: Financial Data Forecasts Estimates and Expectations | TXG | US88025U1097 - marketscreener.com
10x Genomics director John Stuelpnagel sells $1.15m in shares - Investing.com
10x Genomics director John Stuelpnagel sells $1.15m in shares By Investing.com - Investing.com Australia
10x Genomics Director John R. Stuelpnagel Sells 20,000 Shares in August 2026 SEC Filing - Kalkine Media
Insider Selling: 10x Genomics (NASDAQ:TXG) Director Sells 20,000 Shares of Stock - MarketBeat
10 X Genomics Inc Stock (TXG) Financials Data
Revenue
Net Income
Cash Flow
EPS
10 X Genomics Inc Stock (TXG) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Saxonov Serge | Chief Executive Officer |
Aug 26 '26 |
Sale |
63.69 |
10,486 |
667,901 |
1,075,349 |
2.74%
1.77%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):